Depressed Mood and Anhedonia in Healthy Adults (MOOD5)
Primary Purpose
Anhedonia, Depressed Mood
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Nutraceutical
Maltodextrin
Sponsored by
About this trial
This is an interventional prevention trial for Anhedonia focused on measuring saffron extract
Eligibility Criteria
Inclusion Criteria:
- Adults aged between 20 and 65 years (limits included);
- Body Mass Index (BMI) ≥19 and < 30 kg/m²;
- Considered healthy based on their medical history and clinical examination;
- Subjects self-reporting anhedonia based on SHAPS questionnaire. Score ≥ 3 allows the inclusion;
- Subjects with depressive mood disturbance based on POMS depression subscale. Score ≥ 4 allows the inclusion;
- Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
- Affiliated with a social security scheme;
- Agreeing to be registered on the national file of the volunteers in biomedical research.
Exclusion Criteria:
- Suffer from mental health other than mild depressive or anxiety symptoms as measured by the Patient Health Questionnaire (PHQ-9). Volunteers with PHQ-9 score >14 could not be included;
- Having suicidal thoughts: score ≥1 at the item 9 of the PHQ-9;
Diagnosis of medical or psychiatric conditions including (but not limited to):
- psychiatric disorder (other than mild-to-moderate depression symptoms, anhedonia or anxiety),
- neurological disease (Parkinson's, Alzheimer's disease, intracranial haemorrhage, head or brain injury),
- cancer/malignancy,
- cardiovascular disease (other than hypertension),
- Immunological disease,
- endocrine disease (including diabetes or thyroid diseases, Chronic kidney disease, hematological abnormalities);
- Smokers (more than 5 cigarettes per day);
- Uncontrolled hypertension with medication (SBP ≥ 160mmHg or DBP ≥ 100 mmHg) or without medication (SBP ≥ 140mmHg or DBP ≥ 90 mmHg);
- Taking drugs (anxiolytics, antidepressants, antihistamine drug more than 7 day/month) known to have an impact on mental health in the month preceding inclusion and / or likely to consume them during the study and/or Illicit drug;
- Undergoing a psychotherapy in the month preceding inclusion or during the study;
- Consuming more than 3 standard drinks of alcoholic beverage daily;
- Weight change above 10% body weight within the past 6 months before inclusion;
- Currently under prescribed diet regimen, whatever the reason;
- Consuming foods supplement known to have an influence on mental health in the month preceding the inclusion and / or likely to take during the study;
- Consuming more than 50g of chocolate/day;
- For females: Pregnant or planning pregnancy during the study or breastfeeding;
- Any intolerance or allergy documented or suspected to one of the components of the study products;
- Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
- Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study;
- Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
- Presenting a psychological or linguistic incapability to sign the informed consent and to answer the study questionnaires
- Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Sites / Locations
- CEN Experimental
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Nutraceutical
Maltodextrin
Arm Description
Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner. Dietary supplements in capsule form
Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner. Dietary supplements in capsule form
Outcomes
Primary Outcome Measures
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Secondary Outcome Measures
Tension, anger, vigour, fatigue and confusion evaluated by the five POMS sub-scores
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion.
Depression level evaluated by the Center of Epidemiologic Studies Depression scale (CES-D) score
This validated self-reported questionnaire measures levels of depressive symptomatology, with special emphasis on the affective components and depressed mood.
Stress, spleep, anxiety, sadness, energy feeling, attention to others and desire to do things evaluated by Visual Analogic Scales (VAS) score
The visual analog scales will be completed by the subjects at V1 and 2 times a week until 8 weeks. Eight dimensions are observed : stress, spleep, anxiety, happiness, energy feeling, irritability, motivation and pleasure.
Score 0 to 10.
Pleasure feeling evaluated by the Snaith-Hamilton Pleasure Scale (SHAPS) score
The Snaith-Hamilton Pleasure Scale (SHAPS) score is a 14-item self-reported validated questionnaire evaluating the pleasure. It covers four domains of hedonic experience: interest/pastimes, social interaction, sensory experience and food/drink.
A total score can be calculated by adding the responses to each question, ranging from 0 (no anhedonia) to 14 (complete anhedonia).
Quality of life evaluated by the Multicultural Quality of Life Index (MQLI)
This validated self-reported questionnaire is composed of 10 items which cover key aspects of the quality of life, from physical well-being to spiritual fulfilment.
Full Information
NCT ID
NCT05306093
First Posted
February 15, 2022
Last Updated
September 6, 2022
Sponsor
Institut Pasteur de Lille
1. Study Identification
Unique Protocol Identification Number
NCT05306093
Brief Title
Depressed Mood and Anhedonia in Healthy Adults
Acronym
MOOD5
Official Title
Chronic Effect of a Standardized Saffron Extract on Depressed Mood and Anhedonia in Healthy Adults. A Randomized Controlled Double-blind Clinical Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
January 7, 2022 (Actual)
Primary Completion Date
September 1, 2022 (Actual)
Study Completion Date
September 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Institut Pasteur de Lille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to evaluate the effect of nutraceutical supplement on depressed mood and anhedonia in volunteers after 8 weeks of consumption.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anhedonia, Depressed Mood
Keywords
saffron extract
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
94 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nutraceutical
Arm Type
Experimental
Arm Description
Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.
Dietary supplements in capsule form
Arm Title
Maltodextrin
Arm Type
Placebo Comparator
Arm Description
Daily, 2 dietary supplements will be taken orally with some water, the first one during the breakfast and the second one during the dinner.
Dietary supplements in capsule form
Intervention Type
Dietary Supplement
Intervention Name(s)
Nutraceutical
Intervention Description
Food supplements are consumed during 8 weeks by healthy volunteers
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin
Intervention Description
Food supplements are consumed during 8 weeks by healthy volunteers
Primary Outcome Measure Information:
Title
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Time Frame
Baseline (V1)
Title
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Time Frame
at 2 weeks
Title
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Time Frame
at 4 weeks (V2)
Title
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Time Frame
at 6 weeks
Title
Mood disturbance evaluated by the Profile Of Mood States (POMS) total score
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. In our study, a score on POMS depression subscale < 4 does not allow the inclusion.
Time Frame
at 8 weeks (V3)
Secondary Outcome Measure Information:
Title
Tension, anger, vigour, fatigue and confusion evaluated by the five POMS sub-scores
Description
The POMS is a self-reported validated questionnaire assessing six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion.
Time Frame
Baseline (V1) and 1st month (4 weeks (V2)) and between baseline and the end of the study (8 weeks (V3))
Title
Depression level evaluated by the Center of Epidemiologic Studies Depression scale (CES-D) score
Description
This validated self-reported questionnaire measures levels of depressive symptomatology, with special emphasis on the affective components and depressed mood.
Time Frame
Baseline (V1) and each evaluation (at 1 week, 2 weeks, 3 weeks, 4 weeks (V2), 5 weeks, 6 weeks, 7 weeks and the end of the study : 8 weeks (V3))
Title
Stress, spleep, anxiety, sadness, energy feeling, attention to others and desire to do things evaluated by Visual Analogic Scales (VAS) score
Description
The visual analog scales will be completed by the subjects at V1 and 2 times a week until 8 weeks. Eight dimensions are observed : stress, spleep, anxiety, happiness, energy feeling, irritability, motivation and pleasure.
Score 0 to 10.
Time Frame
Baseline (V1) and each week evaluation (1 week, 2 weeks, 3 weeks, 4 weeks (V2), 5 weeks, 6 weeks, 7 weeks and the end of the study : 8 weeks (V3))
Title
Pleasure feeling evaluated by the Snaith-Hamilton Pleasure Scale (SHAPS) score
Description
The Snaith-Hamilton Pleasure Scale (SHAPS) score is a 14-item self-reported validated questionnaire evaluating the pleasure. It covers four domains of hedonic experience: interest/pastimes, social interaction, sensory experience and food/drink.
A total score can be calculated by adding the responses to each question, ranging from 0 (no anhedonia) to 14 (complete anhedonia).
Time Frame
Baseline (V1) and each evaluation (2 weeks, 4 weeks (V2), 6 weeks and 8 weeks (V3)
Title
Quality of life evaluated by the Multicultural Quality of Life Index (MQLI)
Description
This validated self-reported questionnaire is composed of 10 items which cover key aspects of the quality of life, from physical well-being to spiritual fulfilment.
Time Frame
Baseline (V1) and 1st month (4 weeks (V2)) and between baseline and the end of the study (8 weeks (V3))
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Adults aged between 20 and 65 years (limits included);
Body Mass Index (BMI) ≥19 and < 30 kg/m²;
Considered healthy based on their medical history and clinical examination;
Subjects self-reporting anhedonia based on SHAPS questionnaire. Score ≥ 3 allows the inclusion;
Subjects with depressive mood disturbance based on POMS depression subscale. Score ≥ 4 allows the inclusion;
Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
Affiliated with a social security scheme;
Agreeing to be registered on the national file of the volunteers in biomedical research.
Exclusion Criteria:
Suffer from mental health other than mild depressive or anxiety symptoms as measured by the Patient Health Questionnaire (PHQ-9). Volunteers with PHQ-9 score >14 could not be included;
Having suicidal thoughts: score ≥1 at the item 9 of the PHQ-9;
Diagnosis of medical or psychiatric conditions including (but not limited to):
psychiatric disorder (other than mild-to-moderate depression symptoms, anhedonia or anxiety),
neurological disease (Parkinson's, Alzheimer's disease, intracranial haemorrhage, head or brain injury),
cancer/malignancy,
cardiovascular disease (other than hypertension),
Immunological disease,
endocrine disease (including diabetes or thyroid diseases, Chronic kidney disease, hematological abnormalities);
Smokers (more than 5 cigarettes per day);
Uncontrolled hypertension with medication (SBP ≥ 160mmHg or DBP ≥ 100 mmHg) or without medication (SBP ≥ 140mmHg or DBP ≥ 90 mmHg);
Taking drugs (anxiolytics, antidepressants, antihistamine drug more than 7 day/month) known to have an impact on mental health in the month preceding inclusion and / or likely to consume them during the study and/or Illicit drug;
Undergoing a psychotherapy in the month preceding inclusion or during the study;
Consuming more than 3 standard drinks of alcoholic beverage daily;
Weight change above 10% body weight within the past 6 months before inclusion;
Currently under prescribed diet regimen, whatever the reason;
Consuming foods supplement known to have an influence on mental health in the month preceding the inclusion and / or likely to take during the study;
Consuming more than 50g of chocolate/day;
For females: Pregnant or planning pregnancy during the study or breastfeeding;
Any intolerance or allergy documented or suspected to one of the components of the study products;
Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study;
Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
Presenting a psychological or linguistic incapability to sign the informed consent and to answer the study questionnaires
Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zakaria NAFLI, MD
Organizational Affiliation
CEN Experimental
Official's Role
Principal Investigator
Facility Information:
Facility Name
CEN Experimental
City
Dijon
ZIP/Postal Code
21000
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Depressed Mood and Anhedonia in Healthy Adults
We'll reach out to this number within 24 hrs